Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Portfolio Pulse from
Pliant Therapeutics has discontinued its BEACON-IPF Phase 2b trial for bexotegrast in idiopathic pulmonary fibrosis patients due to adverse events, despite early efficacy signs.
March 03, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pliant Therapeutics has stopped its BEACON-IPF Phase 2b trial for bexotegrast due to adverse events, despite some early efficacy. This could impact investor confidence and stock price.
The discontinuation of the trial due to adverse events is likely to negatively impact Pliant Therapeutics' stock price in the short term. Although there were early signs of efficacy, the safety concerns outweigh these, leading to a negative investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100